Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574435 | 0.80 | PTGS2 (0.38) | ALDH1A1MAPTMEN1KMT2AFGFR1 | |
| SCHEMBL11160320 | 0.80 | NAMPT (0.37) | PIK3C3NAMPT | |
| SCHEMBL11968498 | 0.80 | PIK3C3 (0.37) | PIK3C3NAMPTFGFR1KDRTNIK | |
| SCHEMBL4761795 | 0.80 | NAMPT (0.37) | ALDH1A1MAPTMEN1KMT2APIK3C3 | |
| SCHEMBL1434989 | 0.80 | MAPK1 (0.39) | PIK3C3NAMPTTNIK | |
| SCHEMBL18760610 | 0.79 | CYP1A2 (0.36) | ALDH1A1PIK3C3NAMPTFGFR1KDR | |
| SCHEMBL1434596 | 0.79 | PIK3C3 (0.39) | ALDH1A1MAPTPIK3C3NAMPTFGFR1 | |
| SCHEMBL13187100 | 0.79 | PIK3C3 (0.35) | ALDH1A1MAPTMEN1KMT2APIK3C3 | |
| SCHEMBL91324 | 0.73 | KDR (0.60) | FGFR1KDR | |
| SCHEMBL29858603 | 0.73 | KDR (0.60) | FGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-06-29 | — | — | US | disclosed |
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2023287793-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-20210087174-A1 | ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-25 | — | — | US | disclosed |
| US-20200339581-A1 | AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-20120270893-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2081922-B1 | 5,6-Ring annulated indole derivatives and use thereof | SCHERING CORP (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE LLC | 2011-06-30 | — | — | US | disclosed |
| WO-2011068821-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | WO | disclosed |
| US-7919504-B2 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| WO-2010051188-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008082484-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | ALDH1A1 2504/4885MAPT 4473/4885MEN1 1032/4885 |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | ALDH1A1 4269/4885MAPT 2629/4885MEN1 2320/4885 |
| US-20230203000-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, RNASE1 | ALDH1A1 4089/4885MAPT 179/4885MEN1 1755/4885 |
| US-20090298836-A1 | Thiadiazole modulators of PKB | PDK1, PDK2, MTOR | ALDH1A1 2642/4885MAPT 3612/4885MEN1 2594/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | ALDH1A1 4191/4885MAPT 2466/4885MEN1 3329/4885 |
| US-20210087174-A1 | ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, TLR9 | ALDH1A1 1228/4885MAPT 4617/4885MEN1 3727/4885 |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3C3, PRKACA | ALDH1A1 2209/4885MAPT 1095/4885MEN1 1689/4885 |
| US-20200339581-A1 | AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | TLR7, TLR1, TLR9 | ALDH1A1 3139/4885MAPT 4608/4885MEN1 3424/4885 |
| US-20120270893-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | ALDH1A1 105/4885MAPT 1315/4885MEN1 3794/4885 |
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, KIT, GLI1 | ALDH1A1 23/4885MAPT 4472/4885MEN1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.